MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease.

Publication Type	Academic Article
Authors	Helpern J, Lee S, Falangola M, Dyakin V, Bogart A, Ardekani B, Duff K, Branch C, Wisniewski T, de Leon M, Wolf O, O'Shea J, Nixon R
Journal	Magn Reson Med
Volume	51
Issue	4
Pagination	794-8
Date Published	04/01/2004
ISSN	0740-3194
Keywords	Alzheimer Disease, Brain, Magnetic Resonance Imaging
Abstract	The cerebral deposition of amyloid beta-peptide, a central event in Alzheimer's disease (AD) pathogenesis, begins several years before the onset of clinical symptoms. Noninvasive detection of AD pathology at this initial stage would facilitate intervention and enhance treatment success. In this study, high-field MRI was used to detect changes in regional brain MR relaxation times in three types of mice: 1). transgenic mice (PS/APP) carrying both mutant genes for amyloid precursor protein (APP) and presenilin (PS), which have high levels and clear accumulation of beta-amyloid in several brain regions, starting from 10 weeks of age; 2). transgenic mice (PS) carrying only a mutant gene for presenilin (PS), which show subtly elevated levels of Abeta-peptide without beta-amyloid deposition; and 3). nontransgenic (NTg) littermates as controls. The transverse relaxation time T(2), an intrinsic MR parameter thought to reflect impaired cell physiology, was significantly reduced in the hippocampus, cingulate, and retrosplenial cortex, but not the corpus callosum, of PS-APP mice compared to NTg. No differences in T(1) values or proton density were detected between any groups of mice. These results indicate that T(2) may be a sensitive marker of abnormalities in this transgenic mouse model of AD.
DOI	10.1002/mrm.20038
PubMed ID	15065253